Lyell Immunopharma, Inc. LYEL
Updated: 9 Aug 2026
No signal published yet
We already track Lyell Immunopharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Lyell Immunopharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Lyell Immunopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Lyell reported its financial results for the second quarter of 2026, holding approximately $228.0 million in cash and short-term investments to fund operations into Q3 2027. The company also highlighted ongoing clinical progress for its lead CAR T-cell product candidates ronde-cel and LYL273.
What Firelda Watch includes for Lyell Immunopharma, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Lyell Immunopharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Lyell Immunopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more